Approval based on results from the CheckMate-77T trial which showed perioperative Opdivo improved event-free survival compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo Opdivo is now the only PD-(L)1 inhibitor approved for both perioperative and neoadjuvant-only treatment of resectable non-small cell lung cancer in the European Union PRINCETON, NJ, USA I May 16, 2025 I Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has ap

Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, CA and BOSTON, MA, USA I May 16, 2025 I BioMarin Pharmaceutic

Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injection, as the first and the only locally developed enzyme replacement therapy (ERT) for Gaucher disease in China, marks a significant breakthrough for CANbridge Pharmaceuticals and WuXi Biologics in advancing R&D of innovative rare disease therapeutics in China. Velaglucerase-beta for injection is the

Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”) In new echocardiographic analysis, TX45 treatment resulted in sustained hemodynamic effects for 29 days TX45 improved cardiac and pulmonary hemodynamics in PH-HFpEF patients across a range of left ventricular ejection fractions (“LVEF”), including LVEF≥50% and LVEF 41-49%

May 17, 2025 – Analysis Presented at the Heart Failure 2025 Congress Supports Primary Findings, Highlighting Impact of AMVUTTRA, which Delivers Rapid Knockdown of Transthyretin – – Additional 42-Month Data Reinforce Vutrisiran’s Impact on the Risk of All-Cause Mortality and Further Underscore the Effect on Cardiovascular Mortality – – Vutrisiran Demonstrated Substantial Benefit Across a Range of Cardiovascular Events, Notably Reducing Urgent Heart Failure Visits by 46% in the Overall Patient Pop

NEW YORK, May 16, 2025 /PRNewswire/ -- Today, the FDA's approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, marking a pivotal moment in the fight against Alzheimer's disease. This is the first blood test authorized to aid in the diagnosis of Alzheimer's—ushering in a new era of care, alongside recent approvals of disease-modifying therapies. "Today's approval is a transformative moment for patients, clinicians, and the field," said Dr. Howard Fillit, Co-Founder and Chief Science Office

CHICAGO, May 16, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has cleared the first blood test to aid in diagnosis of Alzheimer's disease. The test detects amyloid plaques, a hallmark of Alzheimer's disease, through a blood draw, making it less invasive than other more commonly used diagnostic tools. "Today marks another important step in Alzheimer's disease diagnosis," said Maria C. Carrillo, Ph.D., Alzheimer's Association chief science officer and medical affairs lead. "For

PLEASANTON, Calif., May 16, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, announced today that its Board of Directors has initiated a process to explore strategic alternatives, including a sale, merger or similar transaction involving the Company, to maximize shareholder value. To support this process, Movano Health's Board of Directors has engaged Aquilo Partners as its financial advisor and K&L Gates LLP as its legal counsel. There can be no assurance that

HALETHORPE, Md., May 16, 2025 /PRNewswire/ -- Fzata, Inc. announced today the appointment of a new independent member to the board of directors. The new board member Gianna Arnold, JD, MS is counsel with Saul Ewing, LLP and CEO of NuMoon Technologies, LLC. Gianna is a veteran corporate and transactional attorney with deep biopharma expertise, bringing to the board extensive experience in negotiating strategic alliances as well as conducting due diligence analysis for mergers, acquisitions, licen

Pasco County Patient Care Facility Largest in Statewide Network FORT MYERS, Fla., May 16, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) this week celebrated the opening of its newest patient care facility—the largest of the nearly 100 locations in its statewide network. The state-of-the-art FCS Wesley Chapel Cancer Center at 2895 Hueland Pond Boulevard, Suite 100, Wesley Chapel, FL 33543 provides a comprehensive range of personalized services for adults with can